Adams & Techno Pharma Group is a consolidated Egyptian pharmaceutical platform operating through two sister limited-partnership entities — Adams Pharma and Techno Pharma — both domiciled in Suez and sharing common shareholding and management.
The two entities were founded sequentially to build parallel product pipelines across complementary therapeutic areas under a single operating philosophy: disciplined regulatory practice, selective molecule and dosage-form positioning, and contracted GMP manufacturing through qualified specialist partners.
The founding entity of the Group, holding the senior EDA toll-manufacturer license and the Group’s first fully-registered pharmaceutical product. Operating across primary-care pharmaceutical and food-supplement categories under contracted GMP manufacturing.
Operates the Group’s broader active-registration pipeline under a recently renewed EDA toll-manufacturer license. Holds multiple registered products across cardiovascular, women’s health, and urology categories.
A selection of the Group’s commercially-active products. The full registered portfolio is disclosed under confidentiality to qualified parties.
Active ingredients addressing 14 pharmaceutical sub-segments of the primary-care market. Trade names, EDA pricing, and toll-manufacturer identities are disclosed under confidentiality.
★ Star denotes Fully Registered / Launch Ready status. Three products hold live, valid EDA or NFSA registrations.
Pharmaceutical registration in Egypt operates under Chairman Decree 450/2023, a quota-governed framework in which each active ingredient and dosage form admits a limited number of registered alternatives before the relevant category closes to new entrants.
The Group’s portfolio has been constructed with deliberate attention to this framework, with dosage-form selection calibrated to occupy categories offering favorable entry dynamics — a strategic posture maintained consistently across both entities over a decade of building.
“The EDA pricing committee approvals held by the Group represent the slowest and most uncertain step in Egyptian pharmaceutical registration — already completed for the substantial majority of the portfolio.”
Qualified inquiries from regulated pharmaceutical institutions, healthcare platforms, and established institutional investment parties are considered on a confidential basis and subject to mutual non-disclosure.
Confidential InquiryFor inquiries of a strategic nature — including partnership, licensing, or long-term structural discussions — please complete the form. Messages are reviewed within five business days.
Commercial inquiries, regulatory correspondence, and supplier proposals are not handled through this channel.
Thank you. The Shareholders’ representatives will review your submission within five business days. If the matter proceeds, you will receive a response including the form of mutual non-disclosure agreement and next steps.